New biologic for severe eosinophilic asthma

Benralizumab (Fasenra) is the latest biologic to be launched as add-on therapy in adults with severe eosinophilic asthma that is inadequately controlled despite use of high-dose inhaled corticosteroids and long-acting ß-agonists.

by Sandhiya Sodha
Eosinophilia is associated with worsening asthma severity and decreased lung function, and increased exacerbation frequency. | iStock
Eosinophilia is associated with worsening asthma severity and decreased lung function, and increased exacerbation frequency. | iStock

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package